Arginine suppletion in free TRAM flap Table 6.2 Patient and flap characteristics. All patients Arginine Alanine P‐value (N=18) (N=8) (N=10) Patient demographics (Mean±SEM) Age (y)* 48 (± 1) 47 (± 3) 43 (± 3) 0.18 Bodyweight (kg)* 71 (± 2) 67 (± 4) 71 (± 3) 0.69 BMI (kg/m2)* 24 (± 1) 27 (± 1) 24 (± 1) 0.13 Length of stay (d)* 7 (± 0) 7 (± 0) 7 (± 0) 0.71 Flap records (Mean ± SEM) Ischemia period (min.)* 51 (± 4) 54 (± 11) 44 (± 3) 1.00 Total flap weight (g)* 962 (± 55) 809 (± 111) 999 (± 133) 0.48 Reconstructed breast weight (g)* 751 (± 47) 669 (± 85) 864 (± 79) 0.12 Risk factors Smoking (n,%) # 5 (28%) 2 (25%) 3 (30%) 0.81 Radiation (n,%) # 8 (44%) 2 (25%) 6 (60%) 0.14 Chemotherapy (n,%) # 13 (72%) 4 (50%) 9 (90%) 0.06 * Mann‐Whitney U test (2‐tailed), Chi‐Square test (2‐tailed). Figure 6.3 Patient with Major PFL is shown. This was managed with debridement and/ or reduction in reconstructed breast in order to close defect and achieve a good aesthetic outcome. Usually a reduction on the contralateral side was necessary to achieve adequate symmetry. Results Twenty patients were included in the study. Two patients had total flap loss caused by anastomosis failure. The cause of this anastomosis failure was attributed to technical failure of the anastomosis rather than intervention‐related complication, and therefore data from these patients were excluded from statistical analysis. In the remaining 18 91
Microsoft Word - chapter 0 v1 DB.doc
To see the actual publication please follow the link above